Research and Clinical Trials

Title  

JNJ 64007957MMY1001: A phase I, First-in-Human, Open-Label, Dose Escalatin Study of JNJ 64007957, a Humanized BCMA x CD3 DuoBody in Subjects with Relapsed or Refractory Multiple Myeloma

Brief Description  

Primary: 1. Part I- Dose Escalation to identify the recommended Phase 2 dose(s) RP2D and schedule for JNJ-64007957. 2. Part 2- Dose Expansion to characterize the safety and tolerability of JNJ-64007957 at the RP2D (s).

Who may be Eligible  

Please contact us for eligibility criteria.

Speciality/Disorder  

Multiple Myeloma

Status  

OPEN

Start Date  

05/29/2017

IRB Number  

00021177

Principal Investigator  

Usmani, Saad Zafar

Contact Name  

Tesa M Adams

For More Information, Contact  Tesa  M, Adams
Phone:  980-442-2335 Fax:    
Email:  Tesa.Adams@atriumhealth.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, NC 28204